Edition:
India

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

12.15USD
22 Jun 2018
Change (% chg)

-- (--)
Prev Close
$12.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
795,821
52-wk High
$13.41
52-wk Low
$4.81

Select another date:

Fri, May 4 2018

BRIEF-ImmunoGen Reports Q1 Loss Per Share $0.30

* IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2018 OPERATING RESULTS

BRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine

* IMMUNOGEN ANNOUNCES SUCCESSFUL COMPLETION OF INTERIM ANALYSIS FOR FORWARD I PHASE 3 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT OVARIAN CANCER

BRIEF-Immunogen Inc Files For Potential Mixed Shelf Offering‍​

* IMMUNOGEN INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING‍​ Source text (http://bit.ly/2DablVK) Further company coverage:

BRIEF-Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11‍​

* IMMUNOGEN REPORTS PIPELINE PROGRESS AND 2017 OPERATING RESULTS

BRIEF-Immunogen Says On Jan 8, Co Disclosed It Expects To Report That As Of Dec 31, 2017 It Had Cash And Cash Equivalents Of About $267.1 Mln

* IMMUNOGEN SAYS ON JAN 8, CO DISCLOSED IT EXPECTS TO REPORT THAT AS OF DEC 31, 2017 IT HAD CASH AND CASH EQUIVALENTS OF ABOUT $267.1 MILLION - SEC FILING Source text (http://bit.ly/2CRXR5Q) Further company coverage:

BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies

* IMMUNOGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF IMGN632 FOR HEMATOLOGICAL MALIGNANCIES Source text for Eikon: Further company coverage:

Select another date: